valrubicin has been researched along with Acute Myelogenous Leukemia in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gahrton, G; Peterson, C; Vitols, S | 1 |
| Kanter, PM; Schwartz, HS | 1 |
| Larsson, BS; Mårs, U; Masquelier, M; Pålsson, M; Peterson, CO; Vitols, S | 1 |
3 other study(ies) available for valrubicin and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Significance of the low-density lipoprotein (LDL) receptor pathway for the in vitro accumulation of AD-32 incorporated into LDL in normal and leukemic white blood cells.
Topics: Aged; Doxorubicin; Female; Humans; Kinetics; Leukemia, Myeloid, Acute; Leukocytes; Lipoproteins, LDL; Male; Middle Aged; Receptors, Cell Surface; Receptors, LDL | 1984 |
DNA damage by anthracycline drugs in human leukemia cells.
Topics: Carubicin; Cells, Cultured; Daunorubicin; DNA Repair; DNA, Neoplasm; Doxorubicin; Drug Evaluation; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Prognosis | 1981 |
Low density lipoprotein as a carrier of cytostatics in cancer chemotherapy: study of stability of drug-carrier complexes in blood.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Doxorubicin; Drug Carriers; Female; Humans; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Lipoproteins, LDL; Male; Mice; Mice, Inbred BALB C; Middle Aged; Paclitaxel | 2000 |